Juntendo Urayasu Hospital.
J Appl Clin Med Phys. 2014 May 8;15(3):4434. doi: 10.1120/jacmp.v15i3.4434.
The purpose of this study is to investigate changes in lung tumor internal target volume during stereotactic body radiotherapy treatment (SBRT) using magnetic resonance imaging (MRI). Ten lung cancer patients (13 tumors) undergoing SBRT (48 Gy over four consecutive days) were evaluated. Each patient underwent three lung MRI evaluations: before SBRT (MRI-1), after fraction 3 of SBRT (MRI-3), and three months after completion of SBRT (MRI-3m). Each MRI consisted of T1-weighted images in axial plane through the entire lung. A cone-beam CT (CBCT) was taken before each fraction. On MRI and CBCT taken before fractions 1 and 3, gross tumor volume (GTV) was contoured and differences between the two volumes were compared. Median tumor size on CBCT before fractions1 (CBCT-1) and 3 (CBCT-3) was 8.68 and 11.10 cm3, respectively. In 12 tumors, the GTV was larger on CBCT-3 compared to CBCT-1 (median enlargement, 1.56 cm3). Median tumor size on MRI-1, MRI-3, and MRI-3m was 7.91, 11.60, and 3.33 cm3, respectively. In all patients, the GTV was larger on MRI-3 compared to MRI-1 (median enlargement, 1.54 cm3). In all patients, GTV was smaller on MRI-3m compared to MRI-1 (median shrinkage, 5.44 cm3). On CBCT and MRI, all patients showed enlargement of the GTV during the treatment week of SBRT, except for one patient who showed minimal shrinkage (0.86 cm3). Changes in tumor volume are unpredictable; therefore, motion and breathing must be taken into account during treatment planning, and image-guided methods should be used, when treating with large fraction sizes.
本研究旨在通过磁共振成像(MRI)研究立体定向体部放疗(SBRT)治疗期间肺部肿瘤内部靶区的变化。对 10 例(13 个肿瘤)接受 SBRT(48Gy,连续 4 天)的肺癌患者进行了评估。每位患者接受了 3 次肺部 MRI 评估:SBRT 前(MRI-1)、SBRT 后第 3 次(MRI-3)和 SBRT 完成后 3 个月(MRI-3m)。每次 MRI 均在整个肺部轴面进行 T1 加权成像。每次分割前均进行锥形束 CT(CBCT)扫描。在第 1 次和第 3 次分割前的 MRI 和 CBCT 上,勾画了大体肿瘤体积(GTV),并比较了两者之间的差异。第 1 次(CBCT-1)和第 3 次(CBCT-3)分割前 CBCT 上的中位肿瘤大小分别为 8.68 和 11.10cm3。在 12 个肿瘤中,GTV 在 CBCT-3 上比 CBCT-1 更大(中位增大,1.56cm3)。MRI-1、MRI-3 和 MRI-3m 的中位肿瘤大小分别为 7.91、11.60 和 3.33cm3。在所有患者中,GTV 在 MRI-3 上均大于 MRI-1(中位增大,1.54cm3)。在所有患者中,GTV 在 MRI-3m 上均小于 MRI-1(中位缩小,5.44cm3)。在 CBCT 和 MRI 上,除 1 例患者显示最小缩小(0.86cm3)外,所有患者在 SBRT 治疗周内 GTV 均显示增大。肿瘤体积的变化是不可预测的;因此,在治疗计划中必须考虑运动和呼吸,并在使用大分割剂量治疗时使用图像引导方法。